Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis
- PMID: 20979050
- DOI: 10.1002/hep.23918
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis
Abstract
Presence of bacterial DNA in noninfected patients with cirrhosis and ascites is associated with a marked inflammatory response including activation of the inducible form of nitric oxide synthase and release of nitric oxide, similar to that observed in patients with spontaneous bacterial peritonitis. Although presence of bacterial DNA is associated with an impaired prognosis, no information is available regarding its hemodynamic consequences. Systemic and hepatic hemodynamics before and after a liquid test meal were assessed in a series of 75 noninfected patients with cirrhosis (55 with ascites). Bacterial DNA was measured by polymerase chain reaction. Bacterial DNA was detected only in patients with ascites. Clinical data and liver function were similar in ascitic patients with presence (n = 21) or absence of bacterial DNA (n = 34). Bacterial-DNA(+) patients had significantly lower mean arterial pressure (P = 0.002) and systemic vascular resistance (P = 0.03) than bacterial-DNA(-) patients. Cardiac output, cardiopulmonary pressures, hepatic venous pressure gradient (HVPG), and hepatic blood flow were similar in both groups. Thirty minutes after the test meal, in response to increased blood flow caused by postprandial hyperemia, there was a significantly greater increase in HVPG and impaired hepatic vasorelaxation in bacterial-DNA(+) as compared with bacterial-DNA(-) patients, which indicates hepatic endothelial dysfunction. Indeed, the increase in HVPG after the test meal significantly correlated with serum bacterial DNA concentration.
Conclusion: Presence of bacterial DNA, a marker of bacterial translocation, is associated with aggravation of peripheral vasodilation and with worsening of intrahepatic endothelial dysfunction.
Copyright © 2010 American Association for the Study of Liver Diseases.
Comment in
-
Is bacterial DNA a better marker than endotoxin of bacterial translocation in decompensated cirrhosis?Hepatology. 2011 Jun;53(6):2140-1; author reply 41-2. doi: 10.1002/hep.24303. Hepatology. 2011. PMID: 21425309 No abstract available.
-
Bacterial translocation attenuates the systemic hemodynamic improvement produced by terlipressin in patients with cirrhosis.Hepatology. 2011 Aug;54(2):743-4; author reply 744. doi: 10.1002/hep.24424. Hepatology. 2011. PMID: 21567438 No abstract available.
Similar articles
-
Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites.Liver Int. 2014 Nov;34(10):1504-12. doi: 10.1111/liv.12539. Epub 2014 Apr 4. Liver Int. 2014. PMID: 24661740 Clinical Trial.
-
Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension.Hepatology. 2006 Mar;43(3):485-91. doi: 10.1002/hep.21080. Hepatology. 2006. PMID: 16496307 Clinical Trial.
-
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.Hepatology. 2008 Mar;47(3):978-85. doi: 10.1002/hep.22083. Hepatology. 2008. PMID: 18306221
-
Hemodynamic alterations in liver cirrhosis.Mol Aspects Med. 2008 Feb-Apr;29(1-2):112-8. doi: 10.1016/j.mam.2007.09.010. Epub 2007 Oct 24. Mol Aspects Med. 2008. PMID: 18177931 Review.
-
Fluid retention in cirrhosis: pathophysiology and management.QJM. 2008 Feb;101(2):71-85. doi: 10.1093/qjmed/hcm121. Epub 2008 Jan 9. QJM. 2008. PMID: 18184668 Review.
Cited by
-
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.J Hepatol. 2021 Jul;75 Suppl 1(Suppl 1):S49-S66. doi: 10.1016/j.jhep.2021.01.002. J Hepatol. 2021. PMID: 34039492 Free PMC article. Review.
-
Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.PLoS One. 2015 Mar 17;10(3):e0120642. doi: 10.1371/journal.pone.0120642. eCollection 2015. PLoS One. 2015. PMID: 25781164 Free PMC article.
-
Portal vein thrombosis in cirrhosis: Controversies and latest developments.World J Gastroenterol. 2015 Jun 14;21(22):6769-84. doi: 10.3748/wjg.v21.i22.6769. World J Gastroenterol. 2015. PMID: 26078553 Free PMC article. Review.
-
Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.J Clin Med. 2023 Jan 25;12(3):934. doi: 10.3390/jcm12030934. J Clin Med. 2023. PMID: 36769582 Free PMC article. Review.
-
What's New in Cirrhotic Cardiomyopathy?-Review Article.J Pers Med. 2021 Dec 3;11(12):1285. doi: 10.3390/jpm11121285. J Pers Med. 2021. PMID: 34945757 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical